Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis

Journal of Clinical Rheumatology

Volumn 14, Issue 5, 2008, Pages 294-296

  Eklund, Kari K ^a   Lindstedt, Ken ^b   Sandler, Charlotta ^a   Kovanen, Petri T ^b   Laasonen, Leena ^a   Juurikivi, Annika ^a   Wolff, Henrik ^a   Mykkänen, Marko ^a   Joensuu, Heikki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b WIHURI RESEARCH INSTITUTE   (Finland)

Author keywords

Rheumatoid arthritis; Treatment; Tyrosine kinases

Indexed keywords

CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IBUPROFEN; IMATINIB; PREDNISONE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ACTIVITY; DRUG EFFICACY; DRY SKIN; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LEG EDEMA; MALE; PRIORITY JOURNAL; REFRACTORY PERIOD; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; PAIN ASSESSMENT; TREATMENT OUTCOME;

ADULT; ARTHRITIS, RHEUMATOID; HUMANS; MALE; PAIN MEASUREMENT; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 58949094012     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e318188b1ce     Document Type: Article

References (13)

1. Kindler T, Breitenbuecher F, Marx A, et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood. 2004;103:3644-3654.
2. Ceponis A, Konttinen YT, Takagi M, et al. Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. J Rheumatol. 1998;25:2304-2314.
3. Watanabe N, Ando K, Yoshida S, et al. Gene expression profile analysis of rheumatoid synovial fibroblast cultures revealing the overexpression of genes responsible for tumor-like growth of rheumatoid synovium. Biochem Biophys Res Commun. 2002;294:1121-1129.
4. Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood. 2005;105:3127-3132.
5. Eklund KK, Joensuu H. Treatment of rheumatoid arthritis with Imatinib mesylate: clinical improvement in three refractory cases. Ann Med. 2003;35:362-367.
6. Eklund KK, Remitz A, Kautiainen H, et al. Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients. Rheumatology (Oxford). 2006;45:1573-1575.
7. Miyachi K, Ihara A, Hankins RW, et al. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol. 2003;22:329-332.
8. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association1987 revised Criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
9. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn. 1977;18:481-491.
10. Tetlow LC, Woolley DE. Distribution, activation and tryptase/chymase phenotype of mast cells in the rheumatoid lesion. Ann Rheum Dis. 1995;54:549.
11. Juurikivi A, Laitinen C, Lindstedt K, et al. Induction of apoptosis of synovial tissue mast cells by inhibiting c-kit tyrosine kinase as a potential approach for treatment of arthritis. Ann Rheum Dis. 2005;64: 1126-1131.
12. Paniagua RT, Sharpe O, Ho PP, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest. 2006;116:2633-2642.
13. Sandler C, Joutsiniemi S, Lindstedt KA, et al. Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts. Biochem Biophys Res Commun. 2006;347:31-35.